ASCENT: Patient Subgroup Analyses of Sacituzumab Govitecan vs Single-Agent CT in Metastatic TNBC After ≥2 Prior CT Regimens

June 4-8, 2021; Online at https://conferences.asco.org/am
In subgroup analyses of the phase III ASCENT trial, sacituzumab govitecan maintained benefit and a consistent safety profile vs single-agent chemotherapy among patients aged ≥65 years, among those in the second-line setting with disease TNBC recurrence ≤12 months after (neo)adjuvant therapy, and when compared with individual chemotherapy agents.
Format: Microsoft PowerPoint (.ppt)
File Size: 541 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 31, 2023

Video featuring global experts discussing the latest advances in HER2-low advanced breast cancer, including managing the use and safety of antibody–drug conjugates, from Clinical Care Options (CCO)

person default Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 19, 2023 Expired: January 18, 2024

Downloadable slideset on key points from a podcast on how to optimize personalized care of patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 18, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings